Bietaserpine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

Bietaserpine

DrugBank Accession Number

DB13575

Background

Not Available

Type

Small Molecule

Groups

Experimental

Structure

Similar Structures

Weight: Average: 707.865
Monoisotopic: 707.378180299
Chemical Formula: C₃₉H₅₃N₃O₉

Synonyms

Bietaserpine

External IDs

DL 152
S-1210

Pharmacology

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abaloparatide	Abaloparatide may increase the hypotensive activities of Bietaserpine.
Acebutolol	Acebutolol may increase the hypotensive activities of Bietaserpine.
Aceclofenac	The therapeutic efficacy of Bietaserpine can be decreased when used in combination with Aceclofenac.
Acemetacin	The therapeutic efficacy of Bietaserpine can be decreased when used in combination with Acemetacin.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the antihypertensive activities of Bietaserpine.
Alclofenac	The therapeutic efficacy of Bietaserpine can be decreased when used in combination with Alclofenac.
Aldesleukin	Aldesleukin may increase the hypotensive activities of Bietaserpine.
Alfentanil	Alfentanil may decrease the antihypertensive activities of Bietaserpine.
Alfuzosin	Alfuzosin may increase the hypotensive activities of Bietaserpine.
Aliskiren	Aliskiren may increase the hypotensive activities of Bietaserpine.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: 0P5B94FVD5
CAS number: 53-18-9
InChI Key: WFTSRDISOMSAQC-ZNFOTRSXSA-N
InChI: InChI=1S/C39H53N3O9/c1-9-40(10-2)15-16-42-29-20-25(45-3)11-12-26(29)27-13-14-41-22-24-19-33(37(49-7)34(39(44)50-8)28(24)21-30(41)35(27)42)51-38(43)23-17-31(46-4)36(48-6)32(18-23)47-5/h11-12,17-18,20,24,28,30,33-34,37H,9-10,13-16,19,21-22H2,1-8H3/t24-,28+,30-,33-,34+,37+/m1/s1
IUPAC Name: methyl (1R,15S,17R,18R,19S,20S)-3-[2-(diethylamino)ethyl]-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate
SMILES: CCN(CC)CCN1C2=CC(OC)=CC=C2C2=C1[C@H]1C[C@H]3[C@H](C[C@@H](OC(=O)C4=CC(OC)=C(OC)C(OC)=C4)[C@H](OC)[C@H]3C(=O)OC)CN1CC2

References

General References

Not Available

External Links

ChemSpider: 16735698
ChEBI: 125518
ChEMBL: CHEMBL3989595
ZINC: ZINC000095628218
Wikipedia: Bietaserpine

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00677 mg/mL	ALOGPS
logP	4.81	ALOGPS
logP	4.49	Chemaxon
logS	-5	ALOGPS
pKa (Strongest Basic)	9.81	Chemaxon
Physiological Charge	2	Chemaxon
Hydrogen Acceptor Count	9	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	110.16 Å²	Chemaxon
Rotatable Bond Count	15	Chemaxon
Refractivity	193.83 m³·mol^-1	Chemaxon
Polarizability	79.12 Å³	Chemaxon
Number of Rings	6	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	Yes	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Drug created at June 23, 2017 20:44 / Updated at February 21, 2021 18:54

Bietaserpine

Identification

Structure for Bietaserpine (DB13575)

Pharmacology

Interactions

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra